Drug Type Small molecule drug |
Synonyms Fotagliptin, Futagliptin benzoic acid, 苯甲酸复格列汀 + [3] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date China (28 Jun 2024), |
RegulationPriority Review (China) |
Molecular FormulaC24H25FN6O3 |
InChIKeyCEIKPTLXEHWGMB-XFULWGLBSA-N |
CAS Registry1403496-40-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | China | 28 Jun 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatic Insufficiency | Phase 1 | China | 18 Jul 2025 |
Phase 3 | - | lxgzwmqwcx(steumudzmr) = tjbazjpdus uysycjcwgy (tyspbkjkte ) View more | Positive | 09 Oct 2023 | |||
lxgzwmqwcx(steumudzmr) = rhhbpsefuw uysycjcwgy (tyspbkjkte ) View more |